SCHEMBL4624848

SCHEMBL4624848

O=C(O)C(Cc1ccc2nc(-c3c(F)cccc3F)ccc2c1)NC(=O)C1(c2ccc(Cl)cc2)CCCC1

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 6/20 0.54
ITGAV P06756 1/20 0.54
ITGA4 P13612 9/20 0.47
ITGB7 P26010 6/20 0.45
AVPR1A P37288 5/20 0.43
PTPN1 P18031 4/20 0.42
PTPN2 P17706 3/20 0.42
CDC25B P30305 3/20 0.42
PTPN6 P29350 2/20 0.41
ALB P02768 1/20 0.40
IL2 P60568 1/20 0.40
OXTR P30559 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3313410 0.96 ITGB1 (0.59) ITGB1ITGAVITGA4ITGB7AVPR1A
SCHEMBL3313181 0.92 ITGB1 (0.66) ITGB1ITGAVITGA4ITGB7AVPR1A
SCHEMBL4625262 0.92 ITGB1 (0.66) ITGB1ITGAVITGA4ITGB7AVPR1A
SCHEMBL3316847 0.91 ITGB1 (0.48) ITGB1ITGAVITGA4ITGB7AVPR1A
SCHEMBL4626449 0.90 ITGB1 (0.54) ITGB1ITGAVITGA4ITGB7AVPR1A
SCHEMBL3316562 0.88 ITGA4 (0.60) ITGB1ITGAVITGA4ITGB7
SCHEMBL4652931 0.87 ITGB1 (0.55) ITGB1ITGAVITGA4ITGB7AVPR1A
SCHEMBL3318953 0.87 ITGB1 (0.55) ITGB1ITGAVITGA4ITGB7AVPR1A
SCHEMBL3313019 0.84 ITGB1 (0.47) ITGB1ITGAVITGA4ITGB7AVPR1A
SCHEMBL27621113 0.84 ITGA4 (0.51) ITGB1ITGAVITGA4ITGB7AVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501801-B1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES UCB PHARMA SA (BE) 2008-01-23 EP disclosed
EP-1870402-A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors UCB Pharma, S.A. (BE) 2007-12-26 EP disclosed